Amarin Corp Plc (AMRN)

[north40000]

Methinks CDIO will be stable or increase in share price, with publication of its diagnostic cardiovascular disease test results(JAHA) on prospective patients that do, or do not, evince CVD before or after arrival at a hospital/cardiologist solo or group practice for admittance/examination/treatment. It seems to me AMRN would enjoy share price increase itself in light of increased Vascepa scrips being written by cardiologists in many of the above circumstances with appropriate collaboration with CDIO. Knowledge and data from/of Reduce-It, Evaporate, etc., test results should be on every cardiologist desk